4-(2-fluorophenyl)-2-methyl-5-thiazolecarboxylic acid | 1188184-08-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(2-fluorophenyl)-2-methyl-5-thiazolecarboxylic acid
• 英文别名: 4-(2-fluorophenyl)-2-methylthiazole-5-carboxylic acid；4-(2-fluorophenyl)-2-methyl-1,3-thiazole-5-carboxylic acid
• CAS: 1188184-08-8
• 化学式: C₁₁H₈FNO₂S
• 分子量: 237.254
• InChiKey: FOFVOUCGNPPVAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(2-fluorophenyl)-2-methyl-5-thiazolecarboxylic acid 、 1-(3,5-二氯苯基)哌嗪 在 N-甲基吗啉 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 、 正丁醇 为溶剂， 反应 1.0h， 生成 (4-(3,5-dichlorophenyl)piperazin-1-yl)(4-(2-fluorophenyl)-2-methylthiazol-5-yl)methanone
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Aryloxazole Derivatives as Antimitotic and Vascular-Disrupting Agents for Cancer Therapy

  摘要：

  A series of aryloxazole, thiazole, and isoxazole derivatives was synthesized as vascular-targeting anticancer agents. Antiproliferative activity and tumor vascular-disrupting activity of all of the synthesized compounds were tested in vitro using various human cancer cell lines and HUVECs (human umbilical vein endothelial cells). Several compounds with an arylpiperazinyl oxazole core showed excellent cytotoxicity and metabolic stability in vitro. Among this series, two representative compounds (6-48 and 6-51) were selected and tested for the evaluation of anticancer effects in vivo using tumor-bearing mice. Compound 6-48 effectively reduced tumor growth (42.3% reduction in size) at the dose of 100 mg/kg. We believe that compound 6-48 will serve as a good lead compound for antimitotic and vascular-disrupting agents; further investigation to improve the in vivo efficacy of this series is underway.

  DOI：

  10.1021/jm400840p

文献信息

• [EN] FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS EN TANT QUE MODULATEURS DE RÉCEPTEUR D'OREXINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011050202A1

  公开（公告）日：2011-04-28

  Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  某些二取代的3,8-二氮杂双环[4.2.0]辛烷和3,6-二氮杂双环[3.2.0]庚烷被描述为俄雷昔蛋白抑制剂。这些化合物可能在制药组合物和治疗由俄雷昔蛋白活性介导的疾病状态、紊乱和病况的方法中有用，比如失眠。
• Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
  申请人：Branstetter Bryan James

  公开号：US09062044B2

  公开（公告）日：2015-06-23

  Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  本文描述了某些取代的3,8-二氮杂双环[4.2.0]辛烷和3,6-二氮杂双环[3.2.0]庚烷，它们可用作促进睡眠荷尔蒙的抑制剂。这些化合物可以用于药物组合物和治疗由促进睡眠荷尔蒙活动介导的疾病状态、紊乱和病况，如失眠。
• DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS
  申请人：Branstetter Bryan James

  公开号：US20130137672A1

  公开（公告）日：2013-05-30

  Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  本文描述了某些二取代的3,8-二氮杂双环[4.2.0]辛烷和3,6-二氮杂双环[3.2.0]庚烷，它们可用作促进荷尔蒙分泌的抑制剂。这些化合物可用于制备药物组合物和治疗由荷尔蒙活性介导的疾病状态、失调和病情，如失眠。
• 3-(SUBSTITUTED PHENYL)-5-(SUBSTITUTED HETEROCYCLYL)-1,2,4-TRIAZOLE COMPOUNDS
  申请人：Dow AgroSciences LLC

  公开号：EP1124827A1

  公开（公告）日：2001-08-22
• FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS
  申请人：Janssen Pharmaceutica N.V.

  公开号：EP2491031A1

  公开（公告）日：2012-08-29